Toggle light / dark theme

Scientists have been working for decades on engineered viruses that can hunt down and get inside cancer cells, cause them to burst and spur the immune system to mop up whatever malignant cells might be left behind. Only one such treatment has successfully become an FDA-approved cancer treatment.

That one drug, from Amgen, isn’t selling much. But that small victory a year ago has emboldened others to go forward with their own ideas to advance this approach to cancer therapy, known as oncolytic virus therapy.

One of the aspiring players in the oncolytic virus field, Ottawa, Canada-based Turnstone Biologics, is announcing today it has raised $41.4 million in a Series B venture financing. The round was led by OrbiMed Advisors, and included F-Prime Capital Partners and a couple of existing investors, FACIT and Versant Ventures. The new money will add on to the $11.3 million Series A round from a year ago.

Read more

Researchers at the University of Houston have reported a new method for inducing superconductivity in non-superconducting materials, demonstrating a concept proposed decades ago but never proven.

The technique can also be used to boost the efficiency of known superconducting materials, suggesting a new way to advance the commercial viability of superconductors, said Paul C.W. Chu, chief scientist at the Texas Center for Superconductivity at UH (TcSUH) and corresponding author of a paper describing the work, published Oct. 31 in the Proceedings of the National Academy of Sciences.

“Superconductivity is used in many things, of which MRI (magnetic resonance imaging) is perhaps the best known,” said Chu, the physicist who holds the TLL Temple Chair of Science at UH. But the technology used in health care, utilities and other fields remains expensive, in part because it requires expensive cooling, which has limited widespread adoption, he said.

Read more

Come “ask me anything” right now!!! I’m trying to answer all questions I get asked:


Hi Reddit,

Thank you for having me here. My name is Zoltan Istvan, and I’m a futurist, journalist, and science fiction writer. I’m also the 2016 Presidential candidate for the Transhumanist Party.

For the last 725 days, I have been campaigning full time to spread transhumanism and life extension policies across America and the world. While I never expected to win the US Presidency, my campaign has received a lot of attention—both good and bad—for its emphasis on radical science, technology, secularism, and futurist ideas.

Aging leads to diseases and ultimately death. Time for people to ditch the semantics and recognise that aging and disease are not two mysterious independent processes but are in fact one and the same.


Aging leads to the diseases of aging and the discussion is largely a matter of semantics.

“The concept of aging is undergoing a rapid transformation in medicine. The question has long been asked: Is aging a natural process that should be accepted as inevitable, or is it pathologic, a disease that should be prevented and treated? For the vast majority of medicine’s history, the former position was considered a self-evident truth. So futile was any attempt to resist the ravages of aging that the matter was relegated to works of fantasy and fiction. But today, the biomedical community is rethinking its answer to this question.

The controversy has been fanned, to a great extent, by one Aubrey de Grey, a Cambridge University–trained computer scientist and a self-taught biologist and gerontologist. Over the past decade, de Grey has undertaken an energetic campaign to reframe aging as a pathologic process, one that merits the same level of attention as, say, cancer or diabetes.”

#aging #sens

Read more

Science is making progress on the treatment of aging and age-releated diseases but should you rush out and start your own testing or not? This article weighs up some of the pros and cons.


Senescent cells accumulate with age, and secrete an unfortunate combination of signals that harms organs and tissues in numerous ways, such as via the production of increased chronic inflammation. This is one of the root causes of aging and age-related disease. Safe and effective clearance of senescent cells has been on the SENS rejuvenation biotechnology agenda for fifteen years, but only recently has progress in scientific funding and demonstrations of improved health and life spans in mice snowballed to the point at which startup companies could make a real go of it. Things are moving fairly rapidly in this field now. With the recent $116 million venture investment in UNITY Biotechnology’s work on senescent cell clearance, and other companies angling for their own launch, it is fair to say that this line of research and development is underway for real. Clinical trials of senescent cell clearance will be underway soon, funded by UNITY Biotechnology, and using drug candidates such as navitoclax developed in the cancer research community, noted for their ability to induce apoptosis, a form of programmed cell death. Senescent cells are primed for apoptosis, and it takes little to tip them over the edge in comparison to a normal somatic cell, which means that there may well be quite a large stable of existing drugs that will have some useful effect.

The question here is one that is only now starting to be useful to ask: should we all be running out today to obtain and take a drug (such as navitoclax) or drug combination (such as dasatinib and quercetin) that were shown to clear some fraction of senescent cells in rodents? Certainly there have been no shortage of people chasing after whatever the current hype of the day was in past years; I’m sure you all recall resveratrol and other alleged calorie restriction mimetics or telomere length enhancers. All a waste of time and effort. The difference between the science behind those and the science between senescent cell clearance is considerable, however. The items of the past have all been associated with altering metabolism so as to modestly slow aging, at best, and we have the very good examples of calorie restriction and exercise to show us the immediate bounds of the plausible on that front in our species.

Read more

For the first time, researchers have achieved superconductivity — the phenomenon of electrical conductivity with zero resistance — in a material that’s not a superconductor.

The new technique demonstrates a concept that was first proposed back in the 1970s, but until now had never been proven, and it could lead to ways to make existing superconductors, like the ones used in MRI machines or maglev trains, cheaper and more efficient at higher temperatures.

“Superconductivity is used in many things, of which MRI (magnetic resonance imaging) is perhaps the best known,” said lead researcher Paul C. W. Chu from the University of Houston.

Read more

Rattling around inside a hard drive doesn’t sound like an awful lot of fun — but then, neither does death.

Both eventualities are rather difficult to imagine, but we’ll all have to give them some thought sooner rather than later. Neuroscientist and neuroengineer Randal Koene thinks it’s only going to be another 10 years before we replace parts of the brain with prosthetics.

From there, it’s just a matter of replacing each region systematically, to end up with someone whose brain is immortal and electronic. Could the last person to die have already been born?

Read more